AR and posterior cortical atrophy: Various therapies, including docetaxel chemotherapy, novel androgen receptor signaling inhibitors (ARSIs), poly (ADP-ribose) polymerase (PARP) inhibitors, and radionuclide therapy, have been approved by the United States Food and Drug Administration (FDA) to treat metastatic PCa (Derya et al., 2024).